Creating a shared understanding of the real-world impacts of systemic mastocytosis (SM) is crucial to support and empower those living with the disease. Today, we're unveiling an inaugural art exhibit from our 'Colors of SM: Expressions of Life with Systemic Mastocytosis' program, which illuminates the experiences of people living with SM through the transformative power of creative arts. In collaboration with Twist Out Cancer, Colors of SM pairs talented artists with individuals living with SM to create a unique work of art that reflects their personal journey with the disease. #ColorsOfSM Read more: https://bit.ly/3W4bDIa
Blueprint Medicines
Biotechnology Research
Cambridge, Massachusetts 47,680 followers
Striving to improve and extend patients' lives
About us
Blueprint Medicines is a global, fully integrated biopharmaceutical company that invents life-changing medicines. We seek to alleviate human suffering by solving important medical problems in two core focus areas: allergy/inflammation and oncology/hematology. Our approach begins by targeting the root causes of disease, using deep scientific knowledge in our core focus areas and drug discovery expertise across multiple therapeutic modalities. We have a proven track record of success with two approved medicines in the U.S. and Europe. Leveraging our established research, development, and commercial capability and infrastructure, we now aim to significantly scale our impact by advancing a broad pipeline of programs ranging from early science to advanced clinical trials in mast cell diseases including systemic mastocytosis and chronic urticaria, breast cancer and other solid tumors. Patients are at the center of our mission. We know that in order to make a difference in their lives, we must create an environment where our employees — also known as the Blue Crew — can do their best work. Our culture of transparency, curiosity and diversity empowers us to draw upon a wide range of backgrounds and perspectives to build a conscientious team dynamic. Ideas come from every member of the Blue Crew, from the executive team to new hires. Each day, our teams commit to approach one another with respect and trust: a simple promise that fosters an inclusive and collaborative spirit. We care deeply about the communities where we live and work, and we strive to make a profound impact where it matters most. Learn more about who we are and explore our career opportunities at https://www.blueprintmedicines.com/careers/. Read our community guidelines: https://www.blueprintmedicines.com/community-guidelines/.
- Website
-
http://www.blueprintmedicines.com
External link for Blueprint Medicines
- Industry
- Biotechnology Research
- Company size
- 501-1,000 employees
- Headquarters
- Cambridge, Massachusetts
- Type
- Public Company
- Founded
- 2011
- Specialties
- targeted therapy, systemic mastocytosis, breast cancer, allergy/inflammatory, hematology/oncology, solid tumors, drug design, and mast cell biology
Locations
-
Primary
45 Sidney St
Cambridge, Massachusetts 02139, US
-
Baarerstrasse 8
Zug, 6300, CH
Employees at Blueprint Medicines
Updates
-
We aim to meaningfully impact patients’ lives by actively understanding their perspectives and acting upon what we learn. We’re proud to support The Mast Cell Disease Society, Inc.’s #MastCellCon this weekend in Indianapolis, where we'll hear directly from the mast cell community about their experiences, hopes and aspirations for the future. If you’re attending, come and find the #BlueCrew at the event!
-
This week, our offices worldwide will be closed for our annual Global Summer Well-Being Shutdown. We take our people-first approach seriously and recognize the importance of nurturing a healthy work-life balance. This is the first of two week-long shutdowns we offer each year to provide time to recharge and rest. Thank you to the #BlueCrew for your relentless drive and unwavering commitment to patients throughout the year. For now, we're out of office, so we'll see you next week!
-
Since our founding, we've worked closely with patient communities to ensure our programs incorporate real-world insights and positively impact the patients we serve. From early development through commercialization, we dedicate time to engaging with patients to hear their perspectives, collaborating with patient advocacy groups, creating educational programs, and more. At Blueprint Medicines, patients are our priority as we strive to improve and extend people's lives globally.
-
After more than a decade studying systemic mastocytosis (SM), we've built a deep understanding of mast cells and their role in driving several allergic/inflammatory diseases. We also recognize the KIT receptor as a key regulator of mast cell activation, proliferation, and survival. Using our innovative scientific platform that drives continued discovery of novel therapies, along with our proven ability to inhibit the KIT D816V mutation in SM, we aim to apply our knowledge to other mast cell-driven diseases. Learn how below:
-
"He promised me that if I came to Blueprint, I'd find a warm and welcoming environment that would help me develop a skillset in clinical development." Mentors, advisors and support networks serve as an essential part of shaping one's career path. Listen in as Benjamin Lampson, Medical Director, and Javier I. Muñoz Gonzalez, Ph.D., Director of Clinical Development, recount their journeys to Blueprint Medicines and places they've found supportive environments for professional growth. We're proud that our talented #BlueCrew is comprised of people across multiple disciplines, united by our goal to advance innovative therapies that improve and extend patients' lives.
-
This month, we attended GreenRoots, Inc.'s Evening on the Creek event to celebrate 30 years of their fight for environmental justice, greater quality of life and improved public health. At Blueprint Medicines, we believe human health is inextricably linked with our environment, and responsible stewardship is an important part of our mission to help patients live better lives. By approaching this mission alongside organizations who focus on these efforts every day, we can advance our environmental sustainability goals in a meaningful way. Learn more in our latest Sustainability Report: https://bit.ly/3VaO15r
-
Our core value of Patients First runs through our entire organization, and our Patient Affairs team helps us uphold this promise every day. Their role in building strong, trusting relationships with the advocacy community drives our interactions with patients and helps us deliver treatments that address their needs. Read more from Paul Lim, Director, Patient Affairs on how his team works at the intersection of the patient community’s needs and Blueprint’s aspirations:
-
Join us at #EHA2024! In an oral presentation, we’re sharing data from our PATHFINDER clinical study with a median follow-up of more than three years, and we’re presenting results from our PRISM Survey that highlight patient and healthcare provider perspectives on the burden of systemic mastocytosis. These data reflect our ongoing partnership with the SM community to advance treatment and address patient needs across the spectrum of the disease.
-
Happy Pride! This #PrideMonth, we hosted our annual networking event with OUTbio, the biotech industry’s largest LGBTQ+ professionals group. The event also highlighted organizations/individuals such as BAGLY, Inc., Dani Bernstein, Fenway Health, Stonewall Sports, Inc. Boston, The Nova Comedy Collective and The Theater Offensive. With these partnerships, we collectively spark dialogue, broaden perspectives and strengthen connections. We believe in everyone's right to show up as their authentic selves, and we're committed to creating inclusive spaces that empower our LGBTQ+ community and allies.
Similar pages
Browse jobs
Stock
BPMC
NASDAQ
20 minutes delay
$120.50
0.97 (0.812%)
- Open
- 120
- Low
- 119.02
- High
- 121.9
Data from Refinitiv
See more info on